SciBase Breaks U.S. Reimbursement Barrier with Highmark Coverage for Nevisense

  • SciBase's Nevisense secures first U.S. payer coverage from Highmark Blue Cross Blue Shield on October 14, 2026.
  • Coverage applies to Highmark's 7 million members and self-funded employer groups electing the policy.
  • Highmark cites NCCN and AAD guidelines in supporting the medical necessity of Nevisense for melanoma detection.
  • Policy covers CPT code 0658T for evaluating suspicious pigmented lesions under specific clinical criteria.
  • SciBase aims to expand commercial activity in regions with available reimbursement.

SciBase's Highmark coverage marks a strategic inflection point in its U.S. commercialization strategy, addressing a key barrier to scale in the $4-4.5 million annual skin biopsy market. The decision validates Nevisense's role in melanoma detection and sets a precedent for broader payer adoption. With approximately 6,000 relevant dermatology clinics in the U.S., this milestone could unlock significant growth potential for the company's AI-driven dermatology platform.

Payer Expansion
Whether SciBase can secure additional payer agreements beyond Highmark to accelerate U.S. market penetration.
Commercial Momentum
The pace at which reimbursement coverage converts existing clinical adoption into broader utilization.
Regulatory Alignment
How other payers may reference NCCN and AAD guidelines in evaluating Nevisense for coverage.